VN Research & Consulting
 Like us on facebook  Follow us on twitter  Follow us on LinkedIn  IndiaNotes on Google Plus  IndiaNotes on Pinterest  IndiaNotes on Stumbleupon  Subscribe to our feeds

Stocks  A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
You are here : IndiaNotes >> Research & Analysis >> Companies >> Ipca Laboratories Ltd. >> Research

Ipca Laboratories: Ready to press restart button; Upside 26%

Prabhudas Lilladher | 09 Mar, 2018  | Follow Author | Add to my Favourites 
  • Rate this article
    (Average Rating 0.0 Based on 0 ratings)


We  expect  12%  YoY  earnings  growth  in  FY18E  despite  a)  GST-ridden  India formulation sales and  b)  withdrawal of FDA exception list for US exports, we believe that declining earnings has bottomed out since Q1FY18. The catalyst of recovery to be  driven  by  a)  resumption  of  supply  of  anti-malarial  drugs  to  private  funds  from Q1FY19E,  b)  USFDA  resolutions  of  three  plants,  c)  normalisation  of  India formulations and d) de-risking of API exports with commissioning of Baroda plant.

  Read full report Click here to read the full report

669.05 -1.85
667.55 -3.55
Read More
About Prabhudas Lilladher

Prabhudas Lilladher has a nationwide distribution network, consisting of branches, franchisees and associates, providing a comprehensive gamut of financial services in the Institutional and Retail domain. Their services includes Equity, derivatives; margin funding, mutual funds, PMS, IPOs and online trading.


For more information please write in to [email protected]

Disclaimer: The author has taken due care and caution to compile and analyse the data. The opinions expressed above are only the views of the author, and not a recommendation to buy or sell. Neither the author nor accept any liability whatsoever arising from the use of any of the above contents.

Technical Calls

What are technical calls?

Other Articles

Have a question?